Flightless I Antibody (B-6): sc-377029

Flightless I Antibody (B-6) is a mouse monoclonal IgG1 antibody that detects Flightless I in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Flightless I plays a crucial role in cellular processes, particularly in the organization of the actin cytoskeleton, which is essential for various cellular functions including cell migration, division, and shape maintenance. Flightless I contains an Actin-binding domain that shares homology with the gelsolin family, indicating involvement in actin cytoskeletal rearrangements, which are vital for the dynamic changes that cells undergo during development and in response to external stimuli. Additionally, Flightless I features an N-terminal leucine-rich repeat domain that facilitates protein-protein interactions, further underscoring importance in cellular signaling pathways. Notably, Flightless I localizes predominantly to the nucleus, with subsequent translocation to the cytoplasm upon serum stimulation, highlighting regulatory role in cellular responses. The human FLI gene, located within the Smith-Magenis microdeletion region of chromosome 17 at 17p11.2, is associated with Smith-Magenis syndrome, a condition characterized by a range of developmental and behavioral issues, emphasizing the significance of Flightless I in both normal physiology and disease states. Anti-Flightless I antibody (B-6) is an invaluable tool for researchers investigating the intricate roles of this protein in cellular dynamics and biological processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Flightless I Antibody (B-6) References:

1. Developmentally essential protein flightless I is a nuclear receptor coactivator with actin binding activity.  |  Lee, YH., et al. 2004. Mol Cell Biol. 24: 2103-17. PMID: 14966289
2. Leucine-rich repeat (in Flightless I) interacting protein-1 regulates a rapid type I interferon response.  |  Bagashev, A., et al. 2010. J Interferon Cytokine Res. 30: 843-52. PMID: 20586614
3. Flightless I over-expression impairs skin barrier development, function and recovery following skin blistering.  |  Kopecki, Z., et al. 2014. J Pathol. 232: 541-52. PMID: 24375017
4. Flightless I is a key regulator of the fibroproliferative process in hypertrophic scarring and a target for a novel antiscarring therapy.  |  Cameron, AM., et al. 2016. Br J Dermatol. 174: 786-94. PMID: 26521845
5. Delivery of Flightless I Neutralizing Antibody from Porous Silicon Nanoparticles Improves Wound Healing in Diabetic Mice.  |  Turner, CT., et al. 2017. Adv Healthc Mater. 6: PMID: 27869355
6. Flightless-I mediates the repression of estrogen receptor α target gene expression by the glucocorticoid receptor in MCF-7 cells.  |  Yang, L. and Jeong, KW. 2019. Endocr J. 66: 65-74. PMID: 30369516
7. Flightless I exacerbation of inflammatory responses contributes to increased colonic damage in a mouse model of dextran sulphate sodium-induced ulcerative colitis.  |  Kopecki, Z., et al. 2019. Sci Rep. 9: 12792. PMID: 31488864
8. Attenuation of Flightless I Increases Human Pericyte Proliferation, Migration and Angiogenic Functions and Improves Healing in Murine Diabetic Wounds.  |  Thomas, HM., et al. 2020. Int J Mol Sci. 21: PMID: 32764293
9. The actin polymerization factor Diaphanous and the actin severing protein Flightless I collaborate to regulate sarcomere size.  |  Deng, S., et al. 2021. Dev Biol. 469: 12-25. PMID: 32980309
10. Delivery of Flightless I siRNA from Porous Silicon Nanoparticles Improves Wound Healing in Mice.  |  Turner, CT., et al. 2016. ACS Biomater Sci Eng. 2: 2339-2346. PMID: 33465882

The preferred Flightless I antibody is Flightless I Antibody (116.40): sc-21716.